Premium
P4‐330: LONGITUDINAL BEHAVIOR OF BETA‐AMYLOID IN NEURODEGENERATIVE DEMENTIAS
Author(s) -
Whitwell Jennifer L.,
Tosakulwong Nirubol,
Weigand Stephen D.,
Graff-Radford Jonathan,
Duffy Joseph R.,
Clark Heather M.,
Machulda Mary M.,
Botha Hugo,
Utianski Rene L.,
Schwarz Christopher G.,
Senjem Matthew L.,
Strand Edythe A.,
Ertekin-Taner Nilufer,
Jack Clifford R.,
Lowe Val J.,
Josephs Keith A.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4000
Subject(s) - frontotemporal lobar degeneration , dementia , longitudinal study , apolipoprotein e , medicine , pittsburgh compound b , disease , frontotemporal dementia , psychology , gastroenterology , oncology , pathology
Background: The Translational Biomarkers in Aging and Dementia (TRIAD) cohort aims at describing the biomarker trajectories and interactions as drivers of dementia. As part of the McGill Research Centre for Studies in Aging, TRIAD focuses on advanced personalized and preclinical dementia diagnosis. As of early 2017, the TRIAD registry has recruited 1,100 people and has enrolled 406 participants. Designed to study the interactions between pathophysiological processes in dementia, enrolled in the TRIAD studies are cognitively unimpaired individuals (n1⁄4256), mild cognitively impaired individuals (n1⁄446), sporadic and autosomal dominant Alzheimer’s disease individuals (n1⁄471) and atypical dementia individuals (n1⁄433). TRIAD’s main objectives include; understanding the interactions between amyloid-beta and tau and their role in the progression of brain atrophy and cognitive decline, as well as the role of neuroinflammation, epigenetics and synaptic depletion as mediators of cognitive decline. Importantly, TRIAD constitutes a benchmark cohort for the validation of the next generation of fluid biomarkers.Methods: Inclusion into the TRIAD cohort begins with an over-the-phone screening interview ensuring the participant’s eligibility. At the first visit, participants sign an ethically approved consent form where they agree to donate biofluids; including blood, urine, saliva and cerebrospinal fluid. The second visit consists of an extensive neuropsychological battery. TRIAD cohort uses different tracers in many of their different projects to detect the presence of different protein accumulation in the brain. These tracers include [F]MK6240, [F]FTP, [F]PI2620 and [F]RO948, [F]AZD4694 , [C]PBR or [F]DPA, [F]FEOBV and [C]MRT. During subsequent visits, participants will undergo three PET scans as well as one MRI. The PET scans are dependent on the project in which they are enrolled and on their diagnosis. Results: TRIAD participants return for follow-up clinical and imagery visits 12 months after their baseline visits and then again 24 months later, with a retention rate of 70%. Conclusions: TRIAD cohort presents a distinct opportunity to further understand the progression of Alzheimer’s disease with resources ready to uphold the use of affordable biomarkers, capable of diagnosing and measuring disease progression.